Thomas DiRaimondo, PH.D.


Tommy DiRaimondo, Ph.D. joined the Accelerator in 2013 and currently serves as the Director of Research at Janux Therapeutics, an Avalon portfolio company. Previously, Tommy was the co-founder of Sitari Pharma that spawned from his predoctoral work at Stanford University. Tommy was a key leader in the Sitari Pharma drug discovery and development program whose successful culmination was the acquisition by GlaxoSmithKline. Tommy studied as a predoctoral scholar at Stanford University where he received his Ph.D. in the department of Chemical Engineering. Tommy received a Master’s in Engineering and Bachelor’s in Science and Engineering from the University of Michigan Ann Arbor in the departments of Chemical Engineering and Pharmaceutical Engineering, respectively.

Avalon Bioventures